Dirk C.J.G. van Alewijk

Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients

Cameron Douglas, R. Barnard, Daniel Holder et al. · The Journal of Infectious Diseases · 2019 · 82 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

Tessa Niemeyer‐van der Kolk, Hein van der Wall, G. Hogendoorn et al. · Clinical and Translational Science · 2020 · 51 citations · Full text

Medicine, Dermatology, Pharmacology +14

Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial

Tessa Niemeyer‐van der Kolk, Thomas P. Buters, Lara Krouwels et al. · Journal of the American Academy of Dermatology · 2020 · 44 citations · Full text

Medicine, Dermatology, Immunology +16

High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology

D.T. Geraets, Daniëlle A.M. Heideman, Maurits N.C. de Koning et al. · Journal of Clinical Virology · 2009 · 34 citations

Life Sciences, Genetics, Molecular Genetics +9

Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus‐induced genital lesions

M. Rijsbergen, Rianne Rijneveld, M. Todd et al. · British Journal of Clinical Pharmacology · 2019 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +15